More about

Drug-Eluting Stent

News
May 13, 2022
1 min read
Save

Next-generation DES gains FDA approval

Next-generation DES gains FDA approval

Medtronic announced it received FDA approval for its next generation drug-eluting stent.

News
March 07, 2022
2 min read
Save

Benefits of ultrathin-strut bioresorbable polymer DES remain at 5 years: BIOFLOW-V

Benefits of ultrathin-strut bioresorbable polymer DES remain at 5 years: BIOFLOW-V

An ultrathin-strut bioresorbable polymer sirolimus-eluting stent continued to outperform a durable-polymer drug-eluting stent at 5 years, researchers reported at Cardiovascular Research Technologies.

News
January 15, 2022
2 min read
Save

DCB may be noninferior to DES in setting of small-vessel CAD, regardless of PCI indication

DCB may be noninferior to DES in setting of small-vessel CAD, regardless of PCI indication

According to a prespecified analysis of the BASKET-SMALL 2 trial, reperfusion with a drug-coated balloon in patients with CAD and small vessels may be noninferior to a drug-eluting stent, regardless of the indication for PCI.

News
November 19, 2021
1 min read
Save

STOPDAPT-2 ACS

STOPDAPT-2 ACS

DAPT for 1 months or 12 months in patients with ACS undergoing PCI with a cobalt-chromium everolimus-eluting stent (Xience family, Abbott Vascular).

News
November 02, 2021
2 min read
Save

IVUS-guided PCI yields better long-term CV outcomes in acute MI

IVUS-guided PCI yields better long-term CV outcomes in acute MI

Among patients receiving PCI with a drug-eluting stent, use of IVUS was associated with better CV outcomes, both within and beyond 1 year after the index procedure, according to new research.

News
October 07, 2021
1 min read
Save

Peripheral DES superior to bare-metal stents for treatment of PAD

Peripheral DES superior to bare-metal stents for treatment of PAD

A drug-eluting stent outperformed bare-metal stents for treatment of patients with lesions in the superficial femoral and proximal popliteal arteries, according to results of the EMINENT trial presented at VIVA 21.

News
September 02, 2021
3 min read
Save

STOPDAPT-2 ACS trial inconclusive for 1- vs. 12-month DAPT after PCI and DES implantation

STOPDAPT-2 ACS trial inconclusive for 1- vs. 12-month DAPT after PCI and DES implantation

Despite fewer bleeding events, 1-month dual antiplatelet therapy with clopidogrel failed to prove noninferiority vs. 12-month DAPT after PCI and stent implantation for ACS, according to a presenter.

News
June 17, 2021
1 min read
Save

HOST-EXAM

HOST-EXAM

Clopidogrel or aspirin monotherapy after 6 to 18 months of dual antiplatelet therapy following PCI.

News
June 03, 2021
3 min read
Save

In FDA-designed cohort study, mortality risk not related to paclitaxel-coated devices

In FDA-designed cohort study, mortality risk not related to paclitaxel-coated devices

In the SAFE-PAD cohort study of patients with peripheral artery disease designed in part by the FDA, there was no difference in mortality between those treated with paclitaxel-coated devices and those treated with uncoated devices.

News
May 19, 2021
2 min read
Save

In certain patients, clopidogrel monotherapy better than aspirin after PCI: HOST-EXAM

In certain patients, clopidogrel monotherapy better than aspirin after PCI: HOST-EXAM

In patients who underwent PCI with a drug-eluting stent and took dual antiplatelet therapy for 6 to 18 months, subsequent clopidogrel monotherapy was superior to aspirin monotherapy, according to data from the HOST-EXAM trial.

View more